In parallel, LDHA inhibitors such as FX11 and galloflavin have demonstrated efficacy in preclinical models of lymphoma, pancreatic, and breast cancers by reducing lactate production, disrupting glycolysis, and inducing oxidative stress [112,113]. The gene discussed is LDHA; the disease is breast cancer.